Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

NCT01508000 | Terminated Phase 2

• 2 other identifiers: EORTC-400912010-019238-29
• Study Type: interventional
• Target: 44
• Locations: 6 countries
• Sites: 25

Brief Summary

Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases,resection should be considered after limited chemotherapy. There is consensus for a backbone chemotherapy consisting of fluoropyrimidine + oxaliplatin. FOLFOX was used in the previous EORTC study and is again recommended. The addition of targeted agents to standard chemotherapy in the perioperative strategy for mCRC might increase the ORR and R0 resectability, without significant increase in toxicity, therefore translating to a better outcome. It was therefore decided to design an open label, randomized, multi-center, 3-arm late phase II study. Arm A: (standard) mFOLFOX6 + Surgery Arm B: (experimental) mFOLFOX6 + Bevacizumab + Surgery Arm C: (experimental) mFOLFOX6 + Panitumumab + Surgery

Conditions

Colorectal Cancer Metastatic; Liver Metastases; KRAS Wild Type Colorectal Cancer

Keywords

Liver metastases; Colorectal Cancer; KRAS wild type; FOLFOX; Bevacizumab; Panitumumab; Randomized; Phase II; Perioperative treatment; Adjuvant; Neo-adjuvant; Surgery; Progression Free Survival

Outcome Measures

Primary Outcomes (1)

• Progression free survival

  Increase in progression free survival rate at 1 year in each experimental arm (mFOLFOX6 + bevacizumab or panitumumab) compared to mFOLFOX6 alone arm.

  1 year

Secondary Outcomes (4)

• Pathological response rate

  4 years

• Resection rate

  4 years

• Overall survival

  8 years

• Safety

  4 years

Study Arms (3)

Arm A: modified FOLFOX6 and Surgery

ACTIVE COMPARATOR

6 cycles before and 6 cycles after surgery consisting in: Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h. On day 1 of a 14 day cycle

Drug: FOLFOX6; Procedure: Surgery

Arm B: modified FOLFOX6 + Bevacizumab and Surgery

EXPERIMENTAL

6 cycles before and 6 cycles after surgery consisting in: Hour 0: Oxaliplatin 85 mg/m2 2-h infusion Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion\*. Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h. On day 1 of a 14 day cycle

Drug: FOLFOX6; Biological: Bevacizumab; Procedure: Surgery

Arm C: modified FOLFOX6 + Panitumumab and Surgery

EXPERIMENTAL

Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery 6 cycles before and 6 cycles after surgery consisting in: Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (\> 1000 mg) +/- 15 min. infusion\*. Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h. On day 1 of a 14 day cycle

Drug: FOLFOX6; Biological: Panitumumab; Procedure: Surgery

Interventions

FOLFOX6 DRUG

5-FU, folinic acid, oxaliplatin

Also known as: Chemotherapy

Arm A: modified FOLFOX6 and Surgery; Arm B: modified FOLFOX6 + Bevacizumab and Surgery; Arm C: modified FOLFOX6 + Panitumumab and Surgery

Bevacizumab BIOLOGICAL

Targeted therapy

Also known as: Avastin

Arm B: modified FOLFOX6 + Bevacizumab and Surgery

Panitumumab BIOLOGICAL

Targeted therapy

Also known as: Vectibix

Arm C: modified FOLFOX6 + Panitumumab and Surgery

Surgery PROCEDURE

Arm A: modified FOLFOX6 and Surgery; Arm B: modified FOLFOX6 + Bevacizumab and Surgery; Arm C: modified FOLFOX6 + Panitumumab and Surgery

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically proven CRC with 1 to 8 metachronous or synchronous liver metastases considered to be completely resectable.
• Primary tumor (or liver metastasis) of CRC must be KRAS and NRAS status "wild type".
• Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or for patients with synchronous metastases the primary tumor can be resected (R0) at the same time as the liver metastases if: the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy (3-4 months) before surgery.
• Measurable hepatic disease by RECIST version 1.1.
• Patients must be 18 years old or older.
• A WHO performance status of 0 or 1. Radiotherapy alone is allowed if given pre or post protocol treatment.
• All the following tests should be done within 4 weeks prior to randomization:
• Absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL and white blood cell count (WBC) ≥ 3 x 109/L.
• Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) (to exclude severe renal impairment); no significant proteinuria (urine protein \< 1g/24 hours urine collection) OR urine protein/creatinine ratio \< 1.0 OR 1+ proteinuria on urine dipstick.
• Absence of major hepatic insufficiency (bilirubin ≤ 1.5 x ULN and aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤ 5 x ULN).
• Magnesium ≥ lower limit of normal (LLN)
• Patients with a buffer range from the normal values of +/- 5% for hematology and +/- 10% for biochemistry are acceptable. This will not apply for Renal Function, including Creatinine.
• Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 14 days prior to the first dose of study treatment.
• Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
• Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.

You may not qualify if:

• Evidence of extra-hepatic metastasis (of CRC).
• Previous chemotherapy for metastatic disease or surgical treatment (e.g. surgical resection or radiofrequency ablation) for liver metastasis.
• Previous exposure to EGFR or VEGF/VEGFR targeting therapy within the last 12 months.
• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization.
• Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
• Bleeding diathesis (e.g. hemoptysis of ≥ 1/2 teaspoon or 2.5mL), coagulopathy, or need for administration of full-dose anti-coagulant(s).
• Clinically significant cardiovascular disease, including: uncontrolled hypertension, New York Heart Association (NYHA) class II-IV heart failure, myocardial infarction or unstable angina pectoris, cerebrovascular accident or transient ischemic attack within the past 12 months, peripheral vascular disease ≥ grade 2, serious cardiac arrhythmia requiring medication and other clinically significant cardiovascular disease.
• Peripheral neuropathy \> grade 1 (Common Terminology Criteria for Adverse Events, v4.0) serious wound complications, ulcers, or bone fractures.
• Symptomatic diverticulitis or active or uncontrolled gastroduodenal ulceration.
• History or evidence of interstitial lung disease (e.g. pneumonitis, pulmonary fibrosis)
• Significant disease that, in the investigator's opinion, would exclude the patient from the study. Including known allergy or any other adverse reaction to any of the study drugs (including any of the excipients) or to any related compound, including hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.
• Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
• Participation in another clinical study (except sub studies of this protocol) within the 30 days before randomization and during this study.

Sponsors & Collaborators

• European Organisation for Research and Treatment of Cancer - EORTC: lead
• Amgen: collaborator
• Roche Pharma AG: collaborator

Study Sites (25)

Allgemeines Krankenhaus der Stadt Wien

Vienna, A-1090, Austria

Location

Hopital Universitaire Brugmann

Brussels, Belgium

Location

Universitair Ziekenhuis Gent

Ghent, Belgium

Location

AZ Groeninge Kortrijk - Campus Kennedylaan

Kortrijk, Belgium

Location

AZ Turnhout - Campus Sint Elisabeth

Turnhout, Belgium

Location

Centre Hospitalier Peltzer-La Tourelle

Verviers, Belgium

Location

Institut Sainte Catherine

Avignon, France

Location

Institut Bergonie

Bordeaux, France

Location

CHU Ambroise Pare

Boulogne-Billancourt, F-92104, France

Location

Assistance Publique - Hôpitaux de Paris - Hopital De Bicetre AP-HP

Le Kremlin-Bicêtre, France

Location

Centre Hospitalier Saint Joseph Saint Luc

Lyon, France

Location

Centre Leon Berard

Lyon, France

Location

Hopital Prive Jean Mermoz

Lyon, France

Location

Centre Antoine Lacassagne

Nice, France

Location

Hopital Europeen Georges Pompidou

Paris, 75015, France

Location

Groupe Hospitalier Diaconesses Croix Saint-Simon - Site Reuilly

Paris, France

Location

CHU de Lyon - Centre Hospitalier Lyon Sud

Pierre-Benite (lyon), France

Location

CHU de Reims - Hôpital Robert Debré

Reims, France

Location

Hopital Charles Nicolle

Rouen, France

Location

Centre Hospitalier Privé Saint-Grégoire

Saint-Grégoire, France

Location

CHU Saint-Etienne - CHU de Saint-Etienne - Hopital Nord

Saint-Priest-en-Jarez, France

Location

CHU d'Amiens - CHU Amiens - Hopital Sud

Salouël, France

Location

The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis

Amsterdam, Netherlands

Location

Hospital General Vall D'Hebron

Barcelona, Spain

Location

Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie

Geneva, Switzerland

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Folfox protocol; Drug Therapy; Bevacizumab; Panitumumab; Surgical Procedures, Operative

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Therapeutics; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Bernard Nordlinger, Pr.

  C.H.U. AMBROISE PARE AP-HP, Boulogne-Billancourt, France

  STUDY CHAIR

• Stephane Benoist, Pr.

  HOPITAL DE BICETRE AP-HP, Le Kremlin Bicetre, France

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 9, 2012
• First Posted: January 11, 2012
• Study Start: June 1, 2013
• Primary Completion: September 1, 2016
• Study Completion: September 1, 2016
• Last Updated: October 12, 2016

Record last verified: 2016-10

Locations

NL (1); ES (1); CH (1); BE (5); FR (16); AU (1)